Real-World Health-Related Quality of Life and Treatment Satisfaction in Patients With High-Risk Non-Muscle Invasive Bladder Cancer
Author(s)
Jens Bedke, Prof. Dr.1, Anthony Eccleston, MSc2, Julia Brinkmann, MD MBA3, Abin Koshy, PharmD4, Jane Chang, MPH4, Neil Milloy, BA5, Laure Manuel, MSc5, Jacob Skilling, BSc5, Emilia Biondi, MSci5, Elliott Brown, MRes5, Caitlin Ford, BSc5, Yair Lotan, Prof.6.
1Department of Urology and Transplantation Surgery, Ev Mayr-Stihl Cancer Center, Stuttgart, Germany, 2Pfizer Inc, Surrey, United Kingdom, 3Pfizer Inc, Berlin, Germany, 4Pfizer Inc, New York, NY, USA, 5Adelphi Real World, Bollington, United Kingdom, 6Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
1Department of Urology and Transplantation Surgery, Ev Mayr-Stihl Cancer Center, Stuttgart, Germany, 2Pfizer Inc, Surrey, United Kingdom, 3Pfizer Inc, Berlin, Germany, 4Pfizer Inc, New York, NY, USA, 5Adelphi Real World, Bollington, United Kingdom, 6Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Presentation Documents
OBJECTIVES: This real-world survey used patient reported outcome measures (PROMs) to understand high-risk non-muscle invasive bladder cancer (HR-NMIBC) patients’ health-related quality of life (HRQoL) and treatment satisfaction.
METHODS: Data were drawn from the Adelphi Real World HR-NMIBC Disease Specific Programme™, a cross-sectional survey, with retrospective data collection of physicians and patients in the United States, Canada, Japan, France, Germany, Spain, Italy and the United Kingdom from June to December 2023. Patients voluntarily completed a patient self-completion form.
PROMs included EORTC-QLQ-C30 and NMIBC module (EORTC-QLQ-NMIBC24), scores range from 0-100, with higher scores indicating higher functioning while for symptomology greater symptom severity. EORTC-QLQ-C30 scores were compared to “all cancers-stage I/ II” values using a t-test.
RESULTS: 565 HR-NMIBC patients reported data. At time of data collection, mean (standard deviation [SD]) age was 69.5 (8.94), time since diagnosis was 800.4 days (584.87), and 72% were initially diagnosed with HR-NMIBC.
The mean (SD) EORTC-QLQ-C30 global health score was 64.4 (18.69). Physical functioning 78.6 (18.73) and role functioning 73.2 (20.05) scores were significantly worse (both <0.0001) than all cancers-stage I/II. EORTC-QLQ-NMIBC24 mean (SD) scores for urinary symptoms were 26.5 (16.65), intravesical treatment issues 22.6 (24.32) and sexual function 16.5 (22.03).
The most commonly reported patient symptoms at diagnosis were hematuria (66%), urinary frequency (51%) and urinary dysuria (45%) and at data collection, urinary frequency (43%), urinary urgency (31%) and fatigue (31%).
158 patients received intravesical treatment in the 30 days before data collection. 73% of patients selected satisfied or very satisfied with overall treatment, 75% with the form of treatment administration but 25% found the time needed to complete administrations very or extremely burdensome.
CONCLUSIONS: Whilst patients reported being mostly satisfied with overall treatment and the form of administrations; HR-NMIBC affects patients’ QoL, highlighting the need for novel treatments which reduce burden of administration and improve patients QoL.
METHODS: Data were drawn from the Adelphi Real World HR-NMIBC Disease Specific Programme™, a cross-sectional survey, with retrospective data collection of physicians and patients in the United States, Canada, Japan, France, Germany, Spain, Italy and the United Kingdom from June to December 2023. Patients voluntarily completed a patient self-completion form.
PROMs included EORTC-QLQ-C30 and NMIBC module (EORTC-QLQ-NMIBC24), scores range from 0-100, with higher scores indicating higher functioning while for symptomology greater symptom severity. EORTC-QLQ-C30 scores were compared to “all cancers-stage I/ II” values using a t-test.
RESULTS: 565 HR-NMIBC patients reported data. At time of data collection, mean (standard deviation [SD]) age was 69.5 (8.94), time since diagnosis was 800.4 days (584.87), and 72% were initially diagnosed with HR-NMIBC.
The mean (SD) EORTC-QLQ-C30 global health score was 64.4 (18.69). Physical functioning 78.6 (18.73) and role functioning 73.2 (20.05) scores were significantly worse (both <0.0001) than all cancers-stage I/II. EORTC-QLQ-NMIBC24 mean (SD) scores for urinary symptoms were 26.5 (16.65), intravesical treatment issues 22.6 (24.32) and sexual function 16.5 (22.03).
The most commonly reported patient symptoms at diagnosis were hematuria (66%), urinary frequency (51%) and urinary dysuria (45%) and at data collection, urinary frequency (43%), urinary urgency (31%) and fatigue (31%).
158 patients received intravesical treatment in the 30 days before data collection. 73% of patients selected satisfied or very satisfied with overall treatment, 75% with the form of treatment administration but 25% found the time needed to complete administrations very or extremely burdensome.
CONCLUSIONS: Whilst patients reported being mostly satisfied with overall treatment and the form of administrations; HR-NMIBC affects patients’ QoL, highlighting the need for novel treatments which reduce burden of administration and improve patients QoL.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
RWD152
Topic
Real World Data & Information Systems
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology